BioCentury
ARTICLE | Clinical News

Allergan reports mixed data for acute migraine candidate in second Phase III

May 4, 2018 4:10 PM UTC

Allergan plc (NYSE:AGN) said the 50 mg dose of ubrogepant (MK-1602) met the co-primary endpoints in the double-blind, U.S. Phase III ACHIEVE II trial for the acute treatment of migraine. However, the 25 mg dose of the candidate only met one of the two endpoints.

In February, Allergan reported data from the Phase III ACHIEVE I trial in the indication showing that 50 and 100 mg doses of ubrogepant both met the co-primary endpoints vs. placebo. The company said it remains on track to submit an NDA to FDA in 1H19, and will include all three ubrogepant doses in the submission (see BioCentury, Feb. 9)...